CELL INTELLIGENCE · 肿瘤细胞治疗研究

HR(+) 乳腺癌对 CDK4/6 抑制剂耐药的免疫学机制

An immunological mechanism of resistance to CDK4/6 inhibitors in HR(+) breast cancer.

CDK4/6 抑制剂是 HR + HER2 - 乳腺癌临床管理的核心。